Xeris Biopharma Holdings, Inc. — fact timeline

Xeris Biopharma Holdings, Inc. issued common stock to certain holders (the "Noteholders") of its 8.00% Convertible Senior Notes due 2028 for approximately $23 million in aggregate principal amount of the outstanding 2028 Notes for a combination of cash and shares of the Company's common stock.

“On June 10, 2026, Xeris Biopharma Holdings, Inc. (the “Company”) entered into privately negotiated exchange agreements (the “Exchange Agreements”) with certain holders (the “Noteholders”) of its 8.00% Convertible Senior Notes due 2028 (the “2028 Notes”), pursuant to which the Noteholders have agreed to exchange (the “Exchange”) approximately $23 million in aggregate principal amount of the outstanding 2028 Notes for a combination of cash and shares of the Company’s common stock (the “Exchange Consideration”).”

Xeris Biopharma Holdings, Inc. shareholders approved Advisory Vote to Approve Named Executive Officer Compensation at the 2026-06-04 meeting.

“The Company’s stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission (the “Say-on-Pay Vote”). The Company’s stockholders voted as follows to approve such executive compensation for the Company’s named executive officers pursuant to the Say-on-Pay Vote: For Against Abstain Broker Non-Votes 82,230,204 4,658,035 599,504 40,780,330”

Xeris Biopharma Holdings, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-06-04 meeting.

“The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026: For Against Abstain Broker Non-Votes 125,789,818 1,032,530 1,445,725 —”

Xeris Biopharma Holdings, Inc. shareholders approved Election of Directors at the 2026-06-04 meeting.

“Each nominee was elected by a plurality vote in accordance with the Company’s Amended and Restated Bylaws, as follows: Class II Director Nominee For Withhold Broker Non-Votes Dawn Halkuff 62,581,577 24,906,166 40,780,330 John Johnson 52,665,077 34,822,666 40,780,330”

Xeris Biopharma Holdings, Inc. reported the three months ended March 31, 2026 results: revenue $83,127, net income $2.2 million.

“Three months ended March 31, Change 2026 2025 $ % Product revenue (in thousands): Recorlev $ 49,768 $ 25,530 $ 24,238 95 Gvoke 20,800 20,845 (45) — Keveyis 11,886 11,427 459 4 Product revenue, net 82,454 57,802 24,652 43 Royalty, contract and other revenue 673 2,317 (1,644) (71) Total revenue $ 83,127 $ 60,119 $ 23,008 38”

James Brady was appointed as Director at Xeris Biopharma Holdings, Inc..

“On March 28, 2025, the Board appointed Mr. James Brady to the Company’s Board, effective on such date.”

John Schmid departed as Director at Xeris Biopharma Holdings, Inc..

“On March 28, 2025, Mr. John Schmid informed the Board of his decision to not stand for reelection as a director at the Company’s 2025 annual meeting of stockholders (the “2025 Annual Meeting”).”

Ricki Fairley resigned as Director at Xeris Biopharma Holdings, Inc..

“On March 28, 2025, Ms. Ricki Fairley, a director of Xeris Biopharma Holdings, Inc. (the “Company”), notified the Company of her decision to resign from the Board of Directors (the “Board”) of the Company, effective as of March 28, 2025.”

Ken Johnson retired as Senior Vice President, Global Development and Medical Affairs at Xeris Biopharma Holdings, Inc..

“On February 24, 2025, Mr. Ken Johnson, Pharm.D. notified Xeris Biopharma Holdings, Inc. (the “Company”) of his decision to retire as Senior Vice President, Global Development and Medical Affairs, effective as of April 1, 2025.”

Kevin McCulloch changed role as President and Chief Operating Officer at Xeris Biopharma Holdings, Inc..

“The Board of Directors of Xeris Biopharma Holdings, Inc. (the “Company”) promoted Kevin McCulloch to be President and Chief Operating Officer of the Company, effective as of August 1, 2024.”

Marla S. Persky was appointed as Chairperson of the Board at Xeris Biopharma Holdings, Inc..

“Marla S. Persky, currently a Class III director of the Company, has been appointed by the Board to serve as the Chairperson of the Board, effective as of the Transition Date.”

John Shannon was appointed as Class III Director at Xeris Biopharma Holdings, Inc..

“The Board also approved the appointment of Mr. Shannon as a Class III director, effective as of the Transition Date.”

John Shannon was appointed as Chief Executive Officer at Xeris Biopharma Holdings, Inc..

“John Shannon, currently the Company’s President and Chief Operating Officer, has been appointed by the Board to serve as the Company’s Chief Executive Officer, effective as of the Transition Date.”

Paul R. Edick resigned as Chairman of the Board at Xeris Biopharma Holdings, Inc..

“On July 8, 2024, the Company announced that, effective August 1, 2024 (the “Transition Date”), Paul R. Edick will transition from his role as Chief Executive Officer and Chairman of the Board of Directors of the Company (the “Board”) and will become a Senior Advisor to the Company.”

Paul R. Edick resigned as Chief Executive Officer at Xeris Biopharma Holdings, Inc..

“On July 8, 2024, the Company announced that, effective August 1, 2024 (the “Transition Date”), Paul R. Edick will transition from his role as Chief Executive Officer and Chairman of the Board of Directors of the Company (the “Board”) and will become a Senior Advisor to the Company.”

Xeris Biopharma Holdings, Inc. reported first quarter ended March 31, 2024 results: revenue $40,638, net income $19.0 million, or $0.14 per share. Guidance reaffirmed.

“13,085 12,755 330 2.6 Recorlev 10,599 4,477 6,122 136.7 Product revenue, net 40,263 32,265 7,998 24.8 Royalty, contract and other revenue 375 931 (556) (59.7) Total revenue $ 40,638 $ 33,196 $ 7,442 22.4 Commercial Products • Gvoke® : First quarter net revenue was $16.6 million as compared to $15.0 million in the first quarter of 2023 – an increase of”

Xeris Biopharma Holdings, Inc. reported financial results for the three and twelve months ended December 31, 2023.

“On March 6, 2024, the Company issued a press release containing information about the Company's results of operations and business highlights for the three and twelve months ended December 31, 2023.”

Xeris Biopharma Holdings, Inc. incurred term loan of $15.2 million in additional term loans (the “Tranche 2 Loans”) with Hayfin Services LLP maturing March 5, 2029.

“$15.2 million in additional term loans (the “Tranche 2 Loans” and, together with the Tranche 1 Loans, the “2029 Loans”) on any date after the closing date and through July 15, 2025”

Xeris Biopharma Holdings, Inc. incurred term loan of $200.0 million in term loans (the “Tranche 1 Loans”) with Hayfin Services LLP at (i) 6.95% (or 5.95% if the replacement rate is in effect) plus (ii) the greater maturing March 5, 2029.

“The Amended and Restated Credit Agreement provided for the New Lenders to extend $200.0 million in term loans (the “Tranche 1 Loans”) to Xeris Pharma on the closing date”

Xeris Biopharma Holdings, Inc. entered into Amended and Restated Credit Agreement with Hayfin Services LLP, as administrative agent valued at $200.0 million in term loans (effective 2024-03-05).

“On March 5, 2024, Xeris Biopharma Holdings, Inc. (the “Company”), Xeris Pharmaceuticals, Inc. (“Xeris Pharma”) and certain subsidiary guarantors of the Company entered into an Amended and Restated Credit Agreement and Guaranty (the “Amended and Restated Credit Agreement”) with the lenders from time to time parties thereto (the “New Lenders”) and Hayfin Services LLP, as administrative agent for the New Lenders”

Xeris Biopharma Holdings, Inc. updated its the year ended December 31, 2023 guidance (reaffirmed).

“On January 4, 2024, Xeris Biopharma Holdings, Inc. (the “Company”) issued a press release announcing certain preliminary results for the year ended December 31, 2023.”

Xeris Biopharma Holdings, Inc. reported the three and nine months ended September 30, 2023 results: revenue $48,320, net income Net Loss was $12.2 million, or $0.09 per share, for the three months ended September 30, 2023 and a net loss of $48.9 mi, EPS ($0.09) per share; ($0.36) per share. Guidance raised.

“15,865 13,371 2,494 18.7 Recorlev 8,097 2,520 5,577 nm Product revenue, net 41,697 29,554 12,143 41.1 Royalty, contract and other revenue 6,623 171 6,452 nm Total revenue $ 48,320 $ 29,725 $ 18,595 62.6 nm - not meaningful Commercial Products • Gvoke® : Third quarter 2023 net revenue was $17.7 million as compared to $13.7 million in the third quarter of”

Xeris Biopharma Holdings, Inc. incurred convertible notes of $33,574,000 with qualified institutional buyers at 8.00% per annum maturing July 15, 2028.

“Xeris Biopharma Holdings, Inc., a Delaware corporation (the “ Company ”), and Xeris Pharmaceuticals, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (the “ Guarantor ”), closed the previously announced exchange of $31,975,000 in aggregate principal amount of the Guarantor’s 5.00% Convertible Senior Notes due 2025 (the “ Existing Notes ”) for $33,574,000 in aggregate principal amount of the Company’s new 8.00% Convertible Senior Notes due 2028 (the “ New Notes ”) (the “ Exchange Transactions ”)”

Xeris Biopharma Holdings, Inc. entered into Indenture for 8.00% Convertible Senior Notes due 2028 with U.S. Bank Trust Company, National Association valued at $33,574,000 in aggregate principal amount of 8.00% Convertible Senior Notes due 2028 (effective 2023-09-29).

“On September 29, 2023, Xeris Biopharma Holdings, Inc., a Delaware corporation (the " Company "), and Xeris Pharmaceuticals, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (the " Guarantor "), closed the previously announced exchange of $31,975,000 in aggregate principal amount of the Guarantor’s 5.00% Convertible Senior Notes due 2025 (the " Existing Notes ") for $33,574,000 in aggregate principal amount of the Company’s new 8.00% Convertible Senior Notes due 2028 (the " New Notes ") (the " Exchange Transactions "), in each case, pursuant to the exemption from registration provided by Section 4(a)(2) under the Securities Act of 1933, as amended (the " Securities Act ").”

Xeris Biopharma Holdings, Inc. entered into Exchange Agreements with certain holders of the Guarantor's outstanding 5.00% Convertible Senior Notes due 2025 valued at $31,975,000 in aggregate principal amount of the Existing Notes for $33,574,000 in aggregate princip (effective 2023-09-26).

“On September 26, 2023, Xeris Biopharma Holdings, Inc., a Delaware corporation (the “ Company ”), and Xeris Pharmaceuticals, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (the “ Guarantor ”), entered into separate, privately negotiated exchange agreements (the “ Exchange Agreements ”) with certain holders of the Guarantor’s outstanding 5.00% Convertible Senior Notes due 2025 (the “ Existing Notes ”), pursuant to which the Company will exchange $31,975,000 in aggregate principal amount of the Existing Notes for $33,574,000 in aggregate principal amount of the Company’s new 8.00% Convertible Senior Notes due 2028 (the “ New Notes ”) (the “ Exchange Transactions ”), in each case, pursuant to the exemption from registration provided by Section 4(a)(2) under the Securities Act of 1933, as amended (the “ Securities Act ”).”

Xeris Biopharma Holdings, Inc. reported full-year 2023 results: revenue $145 million to $165 million. Guidance raised.

“performance, and expectations for the remainder of the year gives us the confidence to tighten our 2023 guidance by raising the low end of the total revenue range to $145 to $165 million from $135 to $165 million; reducing cash utilization range to $57 to $67 million from $57 to $77 million; improving year-end cash range to $55 to $65 million. And, we expect to”

Xeris Biopharma Holdings, Inc. reported the three and six months ended June 30, 2023 results: revenue $38.0M, net income $19.8 million, or $0.14 per share, EPS $0.14 per share. Guidance raised.

“expressly set forth by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- XERIS BIOPHARMA REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS Achieved record revenue of $38.0M – a 14% increase from prior quarter, and a 50% increase from same period prior year Ended Q2 with over $80M in cash, cash equivalents and short-term investments Tightens”

Xeris Biopharma Holdings, Inc. shareholders approved To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-07 meeting.

“The Company’s stockholders approved Proposal 2. The votes cast at the Annual Meeting were as follows*: For Against Abstain 87,826,099 820,583 239,701”

Xeris Biopharma Holdings, Inc. shareholders approved To elect Dawn Halkuff, John Johnson and Jeffrey Sherman as Class II directors at the 2023-06-07 meeting.

“The Company held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 7, 2023.”

Xeris Biopharma Holdings, Inc. reported first quarter ended March 31, 2023 results: revenue $33.2M, net income $16.8 million, EPS $0.12 per share. Guidance reaffirmed.

“forth by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- XERIS BIOPHARMA REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS Achieved first quarter total revenue of $33.2M representing 50% growth compared to Q1 2022 Ended Q1 2023 with $95.1M in cash, cash equivalents, and short-term investments Affirms 2023 guidance: total revenue of $135M-$165M;”

Ricki Fairley was appointed as Director at Xeris Biopharma Holdings, Inc..

“On March 29, 2023, Xeris Biopharma Holdings, Inc. (the “Company”) announced the expansion of the Company’s Board of Directors (the "Board") from 8 to 9 members and the appointment of Ricki Fairley to the Board on March 27, 2023.”

Xeris Biopharma Holdings, Inc. engaged Ernst & Young LLP as its auditor.

“On March 13, 2023, the Audit Committee of the Board approved the engagement of Ernst & Young LLP ("E&Y") as its new independent registered public accounting firm to audit the Company's financial statements for the fiscal year ending December 31, 2023.”

Xeris Biopharma Holdings, Inc. dismissed KPMG LLP as its auditor.

“On March 13, 2023, the audit committee (the "Audit Committee") of the board of directors (the "Board") of Xeris Biopharma Holdings, Inc. and subsidiaries (the "Company") approved the dismissal of KPMG LLP ("KPMG") as the Company's independent registered public accounting firm and KPMG was dismissed.”

Xeris Biopharma Holdings, Inc. updated its the fourth quarter and full-year 2022 guidance (initiated).

“Xeris Biopharma Holdings, Inc. (the “Company”) issued a press release containing information about the Company’s results of operations and business highlights for the three and twelve months ended December 31, 2022.”

Xeris Biopharma Holdings, Inc. amended Amendment No. 2 to Credit Agreement and Guaranty with Hayfin Services LLP, as administrative agent, and the lenders parties thereto (effective 2023-01-19).

“On January 19, 2023, Xeris Biopharma Holdings, Inc. (the “Company”) entered into Amendment No. 2 to Credit Agreement and Guaranty (“Amendment No. 2”) with Xeris Pharmaceuticals, Inc. (“Xeris Pharma”), the lenders parties thereto (the “Lenders”) and Hayfin Services LLP, as administrative agent for the Lenders (in such capacity, together with its successors and assigns, the “Agent”), to amend that certain Credit Agreement and Guaranty, dated as of March 8, 2022, as amended by Amendment No. 1 to Credit Agreement and Guaranty dated September 29, 2022 (the “Credit Agreement”), by and among the Company, Xeris Pharma, the subsidiary guarantors from time to time parties thereto, the Agent and the Lenders from time to time parties thereto.”

Xeris Biopharma Holdings, Inc. updated its the year ended December 31, 2022 guidance (reaffirmed).

“XERIS BIOPHARMA UPDATES ITS OUTLOOK FOR 2022 Company expects to end 2022 with over $120M in cash, cash equivalents, and short-term investments and at the top of its net product revenue guidance of $105M-$110M”

Steven Prestrelski was appointed as Chief Scientific Officer at Xeris Biopharma Holdings, Inc..

“the Board appointed (i) John Shannon as President and Chief Operating Officer, (ii) Kenneth Johnson, Pharm.D., as Senior Vice President, Global Development and Medical Affairs, (iii) Beth P. Hecht as Senior Vice President, Chief Legal Officer& Corporate Secretary, and (iv) Steven Prestrelski, Ph.D. as Chief Scientific Officer”

Beth P. Hecht was appointed as Senior Vice President, Chief Legal Officer & Corporate Secretary at Xeris Biopharma Holdings, Inc..

“the Board appointed (i) John Shannon as President and Chief Operating Officer, (ii) Kenneth Johnson, Pharm.D., as Senior Vice President, Global Development and Medical Affairs, (iii) Beth P. Hecht as Senior Vice President, Chief Legal Officer& Corporate Secretary, and (iv) Steven Prestrelski, Ph.D. as Chief Scientific Officer”

Kenneth Johnson was appointed as Senior Vice President, Global Development and Medical Affairs at Xeris Biopharma Holdings, Inc..

“the Board appointed (i) John Shannon as President and Chief Operating Officer, (ii) Kenneth Johnson, Pharm.D., as Senior Vice President, Global Development and Medical Affairs, (iii) Beth P. Hecht as Senior Vice President, Chief Legal Officer& Corporate Secretary, and (iv) Steven Prestrelski, Ph.D. as Chief Scientific Officer”

John Shannon was appointed as President and Chief Operating Officer at Xeris Biopharma Holdings, Inc..

“the Board appointed (i) John Shannon as President and Chief Operating Officer, (ii) Kenneth Johnson, Pharm.D., as Senior Vice President, Global Development and Medical Affairs, (iii) Beth P. Hecht as Senior Vice President, Chief Legal Officer& Corporate Secretary, and (iv) Steven Prestrelski, Ph.D. as Chief Scientific Officer”

Garheng Kong was appointed as Director at Xeris Biopharma Holdings, Inc..

“each of the following members of the Strongbridge board of directors was designated and appointed to the Board: John H. Johnson and Garheng Kong, M.D., PhD, MBA”

John H. Johnson was appointed as Director at Xeris Biopharma Holdings, Inc..

“each of the following members of the Strongbridge board of directors was designated and appointed to the Board: John H. Johnson and Garheng Kong, M.D., PhD, MBA”

Jeffrey W. Sherman was appointed as Director at Xeris Biopharma Holdings, Inc..

“each of the following members of the Xeris board of directors was designated and appointed to the Board: BJ Bormann, Ph.D., Dawn Halkuff, Marla S. Persky, John Schmid and Jeffrey W. Sherman, M.D., FACP”

John Schmid was appointed as Director at Xeris Biopharma Holdings, Inc..

“each of the following members of the Xeris board of directors was designated and appointed to the Board: BJ Bormann, Ph.D., Dawn Halkuff, Marla S. Persky, John Schmid and Jeffrey W. Sherman, M.D., FACP”

Marla S. Persky was appointed as Director at Xeris Biopharma Holdings, Inc..

“each of the following members of the Xeris board of directors was designated and appointed to the Board: BJ Bormann, Ph.D., Dawn Halkuff, Marla S. Persky, John Schmid and Jeffrey W. Sherman, M.D., FACP”

Dawn Halkuff was appointed as Director at Xeris Biopharma Holdings, Inc..

“each of the following members of the Xeris board of directors was designated and appointed to the Board: BJ Bormann, Ph.D., Dawn Halkuff, Marla S. Persky, John Schmid and Jeffrey W. Sherman, M.D., FACP”

BJ Bormann was appointed as Director at Xeris Biopharma Holdings, Inc..

“each of the following members of the Xeris board of directors was designated and appointed to the Board: BJ Bormann, Ph.D., Dawn Halkuff, Marla S. Persky, John Schmid and Jeffrey W. Sherman, M.D., FACP”